Small Molecules
25 September 2017
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Study in Japan of Esaxerenone for Treatment of Essential Hypertension22 September 2017
Dova Pharmaceuticals Announces New Drug Application Submission to FDA for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist22 September 2017
Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus22 September 2017
New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial21 September 2017
FLX Bio Selects Immuno-Oncology Clinical Candidate21 September 2017
BioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication21 September 2017
PharmaMar starts clinical studies with a new compound –PM14- in patients with solid tumors21 September 2017
KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate21 September 2017
Cavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor20 September 2017
Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension20 September 2017
GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations19 September 2017
Imago BioSciences Doses First Patients in Phase 1/2 Study of IMG-7289 in Myelofibrosis19 September 2017
Supernus Provides Update on SPN-810 Phase III Clinical Trials19 September 2017
Karus Therapeutics Announces First Cancer Patients Dosed with KA2507, a Small Molecule HDAC6-Selective Inhibitor, in a Phase I Clinical Trial19 September 2017
Principia Biopharma Presents Late-Breaking Interim Phase 2 Data of PRN1008 in Pemphigus at European Academy of Dermatology and Venereology Meeting19 September 2017
Optinose Announces FDA Approval of XHANCE™ (fluticasone propionate) Nasal Spray for the Treatment of Nasal Polyps19 September 2017
Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US18 September 2017
TECENTRIQ GO29695 (NCT02431208) and BO29562 (NCT02631577) partial clinical hold reactive statementNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports